Company Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan.
The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Javier Szwarcberg |
Contact Details
Address: 611 Gateway Boulevard, Suite 740 South San Francisco, California 94080 United States | |
| Phone | 415 655 4168 |
| Website | sprucebio.com |
Stock Details
| Ticker Symbol | SPRB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001683553 |
| CUSIP Number | 85209E109 |
| ISIN Number | US85209E1091 |
| Employer ID | 81-2154263 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer and Director |
| Michael G. Grey | Executive Chairman |
| Samir M. Gharib CPA, M.B.A. | President and Chief Financial Officer |
| Dr. Kirk Ways M.D., Ph.D. | Chief Medical Officer and Director |
| P. J. Ramtin | Senior Vice President of Business Operations |
| Heidi Petersen M.P.H. | Senior Vice President of Regulatory and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 15, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 15, 2025 | 10-K | Annual Report |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 10, 2025 | SCHEDULE 13D/A | Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |